13 Matching Annotations
  1. Jun 2025
  2. 52.53.155.43 52.53.155.43
    PDF-html.html
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    52.53.155.43/095f1297dc44b7c13374b7a22bd6385cbe7ad75d/PDF-html.html
  3. Apr 2025
  4. www.sciencedirect.com www.sciencedirect.com
    Phase 2 trial of perioperative chemo-immunotherapy for gastro-esophageal adenocarcinoma: The role of M2 macrophage landscape in predicting response
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    sciencedirect.com/science/article/pii/S2666379125001181
  5. Jan 2025
  6. www.sciencedirect.com www.sciencedirect.com
    IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trial
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    sciencedirect.com/science/article/pii/S2666634024004872
  7. Sep 2024
  8. www.sciencedirect.com www.sciencedirect.com
    Proteogenomic and metabolomic characterization of human glioblastoma
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    sciencedirect.com/science/article/pii/S1535610821000507
  9. May 2024
  10. aacrjournals.org aacrjournals.org
    Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer harboring HRR mutations: interim results of the UNITO-001 phase 2 prospective trial
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    aacrjournals.org/clincancerres/article/30/5/959/734303/Niraparib-plus-Dostarlimab-in-Pleural-Mesothelioma
  11. Feb 2024
  12. 52.53.155.43 52.53.155.43
    delete-html.html
    2
    Visit annotations in context

    Tags

    Annotators

    URL

    52.53.155.43/cf598364e2561e3de494d0af6acdee45e74e56b3/delete-html.html
  13. Oct 2023
  14. www.sciencedirect.com www.sciencedirect.com
    Real-world efficacy and safety of low-dose pembrolizumab in patients with advanced and refractory gynecologic cancers
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    sciencedirect.com/science/article/pii/S0929664623003996
  15. Jun 2023
  16. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC10233355/
  17. Jan 2023
  18. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    Case report: Durable response after pembrolizumab in combination with radiation - induced abscopal effect in platinum - refractory metastatic endometrial clear cell carcinoma
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC9797856/
  19. Oct 2022
  20. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    Tumoral PD-L1 does not impact time to treatment discontinuation in EGFR mutated non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor—a Danish cohort study
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC9554682/
  21. Sep 2022
  22. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    Correlation between PD-L1 expression and radiomic features in early-stage lung adenocarcinomas manifesting as ground-glass nodules
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC9513584/
  23. Feb 2022
  24. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    PD-L1 expression and patient outcomes in gastrointestinal neuroendocrine neoplasm: a meta-analysis
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC8798646/